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atriuretic Peptides as Predictors of
on-Sudden and Sudden Cardiac Death After
cute Myocardial Infarction in the Beta-Blocking Era
ari M. Tapanainen, MD,* Kai S. Lindgren, MD,* Timo H. Ma¨kikallio, MD,* Olli Vuolteenaho, MD,†
uhani Leppa¨luoto, MD,† Heikki V. Huikuri, MD, FACC*
ulu, Finland
OBJECTIVES This prospective study tested whether the natriuretic peptides predict cardiac death among
patients using beta-blocking therapy after an acute myocardial infarction (AMI).
BACKGROUND Natriuretic peptides have provided prognostic information after AMI, but their predictive
value has not been well established in the era of beta-blocker use.
METHODS A series of 521 patients (mean age 61  10 years) with AMI was included in the study. The
end points were total mortality and non-sudden and sudden cardiac death (SCD). Plasma
concentrations of atrial natriuretic peptide (ANP), N-terminal atrial natriuretic propeptide
(N-ANP), brain natriuretic peptide (BNP), and ejection fraction (EF) were analyzed before
hospital discharge. The cardiac medication was optimized (e.g., adherence to beta-blocking
therapy was 97% at discharge and 95% at one year after AMI).
RESULTS During a mean follow-up of 43  13 months, total mortality was 11.5% (60/521), cardiac
mortality was 6.3% (33/521), and 3.1% (16/521) experienced SCD. On univariate
analysis, high levels of all measured peptides and low EF predicted the occurrence of
non-SCD (p  0.001 for all). Peptides and EF also predicted the occurrence of SCD (p
 0.05), with elevated BNP (23.0 pmol/l) being the most powerful predictor (hazard
ratio [HR] 4.4, 95% confidence interval [CI] 1.4 to 13.8; p  0.01). After adjusting for
clinical variables, only elevated BNP (HR 3.9, 95% CI 1.2 to 12.3, p  0.02) and low EF
(40%) (p  0.03) remained as significant predictors of SCD.
CONCLUSIONS Natriuretic peptides retain their prognostic value in the beta-blocking era among survivors of
AMI. Elevated BNP provides information on the risk of subsequent SCD, independent of
clinical variables and left ventricular EF. (J Am Coll Cardiol 2004;43:757–63) © 2004 by
the American College of Cardiology Foundationm
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ahanges in the neuroendocrine system and various neuro-
ormonal markers, such as natriuretic peptides, have been
hown to provide prognostic information among patients
urviving an acute myocardial infarction (AMI). Concen-
rations of atrial (A-type) natriuretic peptide (ANP),
-terminal pro-ANP (N-ANP), brain (B-type) natriuretic
eptide (BNP), and N-terminal pro-BNP (N-BNP) have
een shown to predict both total and cardiac mortality when
easured after AMI (1–9). However, a majority of the
tudies assessing the prognostic power of vasoactive peptides
ere performed in the era before the introduction of
ptimal medical therapy (e.g., beta-blocking therapy),
hich has major influences on the outcome of post-AMI
atients, particularly on the incidence of sudden cardiac
eath (SCD) (10–13). Therefore, their prognostic signifi-
ance among patients treated with contemporary guidelines
s not well established.
From the *Division of Cardiology, Department of Internal Medicine, Oulu
niversity Hospital, Oulu; and †Department of Physiology, Oulu University, Oulu,
inland. This study was supported by grants from Aarne and Aili Turunen’s
oundation, the Finnish Foundation for Cardiovascular Research, and the Medical
ouncil of the Finnish Academy of Science, Helsinki, Finland. Melvin D. Cheitlin,
D, acted as Guest Editor of this paper.
Manuscript received May 22, 2003; revised manuscript received August 15, 2003,dccepted September 16, 2003.Prediction of SCD after AMI is still a challenge. Several
ethods of prediction have been proposed (14–22), but
one of them, except the measurement of left ventricular
LV) systolic function, is in routine clinical use for screening
atients for candidacy of anti-arrhythmic therapy, such as
n implantable cardioverter-defibrillator (ICD) (19). A
ecent study among patients with chronic heart failure (HF)
nd depressed LV function showed that measurement of
lasma level of BNP provides information on the risk of
ubsequent SCD (20). However, the predictive value of
atriuretic peptides as predictors of SCD has not been
ssessed in general post-AMI populations. This single-
enter study was designed to assess the prognostic power of
arious natriuretic peptides as predictors of both non-SCD
nd SCD after AMI among patients in whom cardiac
edication, particularly beta-blocking therapy, was opti-
ized according to current guidelines.
ETHODS
atients. A single-center prospective study—the Multiple
isk Factor Analysis Trial (MRFAT)—was started in 1996
t the Division of Cardiology, University of Oulu, aiming to
etermine the prognostic power of several noninvasive risk
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Natriuretic Peptides as Predictors After AMI March 3, 2004:757–63arkers of mortality in patients who had survived an AMI.
he results of the predictive power of specific arrhythmia
isk variables in the same population have been reported
arlier (21,22). The patients were recruited to participate
uring the first seven days after AMI. The qualifying
iagnosis and inclusion and exclusion criteria have been
escribed in detail in previous reports (21,22). The present
tudy describes the results of patients who consented to a
ubstudy assessing the prognostic power of natriuretic
eptides.
To optimize treatment, aspirin (or warfarin) and beta-
locking drugs were given to all patients, angiotensin-
onverting enzyme inhibitors to patients with a left ventric-
lar ejection fraction (EF) below 40%, and lipid-lowering
gents to patients with increased levels of total cholesterol,
henever no contraindications for such medications existed
nd the patients consented to start the medication. The dose
f beta-blocking therapy was adjusted to achieve a resting
eart rate between 50 and 60 beats/min. Special emphasis
as paid to long-term adherence to the beta-blocking
edication. All patients had a telephone contact at 6, 24,
6, 48, and 60 months after the AMI and a clinical visit at
he outpatient clinic 12 months after AMI. During these
ontacts, the medication and symptoms of the patients were
hecked. All patients were required to give written, in-
ormed consent, and the study was approved by the Ethical
ommittee of the institution.
lood sampling and assay for natriuretic peptides. The
lood sample for natriuretic peptides was taken 7  2 days
fter AMI through an intravenous cannula into EDTA
acuum tubes. The samples were placed on ice and centri-
uged at 4°C for 10 min, and the plasma was stored at
70°C. The assay was performed as previously described
23,24).
eft ventricular function. Left ventricular systolic func-
ion was measured with two-dimensional echocardiography,
sing wall motion index analysis at three to seven days after
MI. A rough estimate of LVEF can be calculated by
ultiplying the wall motion index by 30. Details of this
ethod and its use have been described earlier (21,25,26).
nd points. The survival status was checked during the
Abbreviations and Acronyms
AMI  acute myocardial infarction
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
CI  confidence interval
EF  ejection fraction
HF  heart failure
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
LV  left ventricular
N-ANP  N-terminal atrial natriuretic propeptide
SCD  sudden cardiac deathollow-up from the National Register of Mortality if the tatient could not be contacted. In cases of death, the reasons
or death were verified by hospital and autopsy records and
y either relatives or the primary physicians who had
itnessed the death. The mode of death was classified as
ardiac or noncardiac, with cardiac mortality being the
rimary end point. The cardiac deaths were defined as
udden or non-sudden deaths by two independent investi-
ators. Cardiac death was defined as “sudden” if it was: 1)
witnessed death occurring within 60 min from the onset
f new symptoms, unless a cause other than cardiac was
bvious; 2) an unwitnessed death (24 h) in the absence
f pre-existing progressive circulatory failure or other
auses of death; or 3) a death during attempted resusci-
ation (25,26).
tatistical analysis. The data were analyzed using SPSS
oftware (SPSS version 10.0, SPSS Inc., Chicago, Illinois).
nivariate comparisons of the baseline characteristics between
he deceased and survivors were performed with the chi-square
est for categorical variables. For continuous variables, one-way
nalysis of variance was used with either the Bonferroni
ultiple comparison test or Tamhane’s T2 test (27), depending
n Levene’s statistic for homogeneity of variance (28). As for
able 1. Clinical Features of the Patients
ales/females 403/118 (77%/23%)
ge (yrs, mean  SD) 61.1  10.0
linical features
Hypertension 249 (48%)
Diabetes 108 (21%)
Previous infarction 105 (20%)
Previous CABG 29 (6%)
Congestive heart failure 51 (10%)
COPD 39 (8%)
Stroke or TIA 51 (10%)
Smoking (current or former) 359 (69%)
eatures before discharge
Type of infarction
Q-wave 267 (51%)
Non–Q-wave 230 (44%)
Indeterminate 24 (5%)
Site of infarction
Anterior 243 (47%)
Inferior 234 (45%)
Indeterminate/other 44 (8%)
Thrombolytic therapy or primary PTCA 245 (47%)
NYHA class at discharge
I/II 455 (88%)
III/IV 62 (12%)
herapy
Beta-blockers 504 (97%)
ACE inhibitors or AT II receptor antagonists 227 (44%)
In patients with EF 40% 69 (84%)
ASA or warfarin 495 (95%)
Statins 235 (45%)
In patients with LDL cholesterol
3.0 mmol/l
106 (72%)
CE  angiotensin-converting enzyme; ASA  acetylsalicylic acid; AT II 
ngiotensinogen II; CABG  coronary artery bypass grafting; COPD  chronic
bstructive pulmonary disease; EF  ejection fraction; LDL  low-density lipopro-
ein; NYHA  New York Heart Association; PTCA  percutaneous transluminal
oronary angioplasty; TIA  transient ischemic attack.he Bonferroni test, up to four comparisons were included in
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March 3, 2004:757–63 Natriuretic Peptides as Predictors After AMIhe analysis. The optimal cut-off points for all predictive
ariables were determined as follows: various cut-off points
ere tested in Cox regression analysis using cardiac death as
he end point. This was done in fifth-percentile steps above the
edian value for vasoactive peptides and in fifth-percentile
teps up to the median value for EF. The value that resulted in
he statistically most significant hazard ratio (HR) in the Cox
nalysis was chosen as the “best” cut-off value. In addition to
his, the highest quartile of vasoactive peptides—or the lowest
uartile of EF—was chosen as another cut-off point for the
urvival analyses in order to generate subgroups of comparable
izes. We did not use previously defined cut-off points for
asoactive peptides, because these cut-off points have been
educted from studies on diverse patient materials, and their
alidity has not been proved in current post-AMI patient
roups.
The relative risk and 95% confidence interval (CI) were
alculated for each categorical variable as a predictor of
ardiac and sudden arrhythmic mortality in the Cox regres-
ion model. To estimate the independent power of the
ariables in predicting cardiac and sudden arrhythmic mor-
ality, age, diabetes, and New York Heart Association
unctional class were included in the Cox proportional
azards regression analyses. Kaplan-Meier estimates of the
able 2. Ejection Fraction and Natriuretic Peptides in Survivors
Survivors
(n  461)
Noncardiac
(n  27)
jection fraction* 46.2  9.00 46.8  8.10
NP (pmol/l) 54.7  83.7 65.5  64.0
-ANP (pmol/l) 594  360 973  621‡
NP (pmol/l) 26.1  28.0 58.8  80.0‡
Ejection fraction calculated by multiplying the wall motion index by 30. †p  0.001,
SD.
ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide; N-ANP  N
able 3. Predictors of Sudden Cardiac Deaths and Non-Sudden
or Age, Diabetes, and New York Heart Association Class)
Sudden C
RR 95%
nivariate analysis
ANP 67.5 pmol/l (highest quartile) 2.06 0.77–
ANP 37.6 pmol/l (best cut-off) 4.12 1.33–
N-ANP 786 pmol/l (highest quartile) 2.36 0.88–
N-ANP 973 pmol/l (best cut-off) 3.39 1.23–
BNP 33.9 pmol/l (highest quartile) 3.74 1.35–
BNP 23.0 pmol/l (best cut-off) 4.38 1.39–
EF 40% (lowest quartile) 3.45 1.30–
EF 30% (best cut-off) 4.94 1.40–
ultivariate analysis
ANP 67.5 pmol/l (highest quartile) 1.76 0.64–
ANP 37.6 pmol/l (best cut-off) 3.65 1.17–
N-ANP 786 pmol/l (highest quartile) 1.80 0.63–
BNP 33.9 pmol/l (highest quartile) 3.39 1.22–
BNP 23.0 pmol/l (best cut-off) 3.89 1.23–
EF 40% (lowest quartile) 3.05 1.13–
EF 30% (best cut-off) 3.68 1.02–I  confidence interval; RR  relative risk; other abbreviations as in Tables 1 and 2.istribution of times from baseline to the end point were
omputed, and log-rank analysis was performed to compare
he survival curves between the groups. A value p  0.05
as considered significant.
ESULTS
sample of 521 patients was included in the study. The
ajority of them (97%) were receiving beta-blockers at
ischarge, and 95% had continued receiving beta-blocking
herapy at one year after AMI. Other clinical characteristics
f the patients are shown in Table 1. Total mortality was
1.5% (60 of 521 patients) after the mean follow-up of 43
3 months (range 12 to 60 months). Cardiac mortality was
.3% (33 of 521 patients). The incidence of SCD during
his period was 3.1% (16 of 521 patients).
nivariate predictors of mortality. The mean values of
asoactive peptides were significantly higher and EF was
ower among those who died from a cardiac cause, as
ompared with survivors (Table 2). In general, peptides
ere elevated among those who experienced either non-
CD or SCD. However, the BNP level was not significantly
igher among those with non-SCD than among survivors.
he univariate relative risks of the test results as predictors
f SCD and non-SCD are shown in Table 3. Reduced EF
atient Groups According to Type of Mortality
Cardiac
n  33)
Sudden Cardiac
(n  16)
Non-Sudden Cardiac
(n  17)
.3  10.5† 39.9  10.8‡ 38.7  10.5§
.2  115.7† 83.1  72.4 145.3  141.0†
7  558§ 893  669‡ 1,041  430§
.5  55.9† 54.4  76.1‡ 47.2  33.5
0.05, and §p  0.01 compared with survivors. Data are presented as the mean value
inal pro-ANP.
iac Deaths in Univariate and Multivariate Analyses (Adjusted
Deaths Non-Sudden Cardiac Deaths
p Value RR 95% CI p Value
0.152 6.79 2.39–19.31 0.000
0.014 6.75 1.94–23.53 0.003
0.089 7.22 2.54–20.49 0.000
0.018 6.39 2.47–16.57 0.000
0.011 2.74 1.06–7.10 0.038
0.011 4.99 1.63–15.31 0.005
0.013 4.80 1.83–12.61 0.001
0.013 8.31 2.92–23.64 0.000
0.271 4.70 1.65–13.41 0.004
0.026 4.55 1.30–15.87 0.018
0.270 3.23 1.21–8.59 0.019
0.037 1.42 0.53–3.78 0.483
0.021 2.33 0.74–7.36 0.149
0.027 3.71 1.40–9.80 0.008
0.047 3.48 1.17–10.38 0.025and P
(
39
115
96
50
‡p Card
ardiac
CI
5.57
12.82
6.33
9.32
10.32
13.77
9.20
17.36
4.81
11.42
5.09
9.45
12.33
8.21
13.29
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Natriuretic Peptides as Predictors After AMI March 3, 2004:757–63nd high levels of all natriuretic peptides predicted both
on-SCD and SCD during the follow-up period at the
ut-off points tested.
ultivariate predictors of mortality. After adjusting for
linical variables, high levels of vasoactive peptides and
educed EF remained as independent predictors of cardiac
ortality at all cut-off points tested (Table 3). Non-SCD
as predicted by elevated ANP and N-ANP at both cut-off
oint levels. Elevated BNP was not a significant predictor of
on-SCD. However, elevated BNP (at both cut-off point
evels) predicted the occurrence of SCD, whereas elevated
NP and N-ANP were not as powerful predictors of SCD
han non-SCD. Reduced EF similarly predicted both SCD
nd non-SCD (Table 3).
The levels of all measured natriuretic peptides had a
ignificant inverse correlation (ANP: r  0.123, p 
igure 1. Kaplan-Meier survival curves for cardiac mortality of patient g
easurements: (A) for atrial natriuretic peptide (ANP), the best cut-off po
N-ANP), the best cut-off point was at the 85th percentile; (C) for brain
or EF, the cut-off point was at the lowest quartile..01; N-ANP: r  0.351, p  0.001; and BNP: r  t0.370, p  0.001) to LVEF, but they still provided
ndependent prognostic information after adding EF into
he Cox regression model (e.g., elevated BNP at the best
ut-off point predicted cardiac death [HR 2.97, 95% CI
.29 to 6.83; p  0.01] and SCD [HR 3.86, 95% CI 1.22
o 12.23; p  0.02]).
The Kaplan–Meier survival curves for peptides and EF
re shown in Figure 1. The cardiac mortality curves start to
iverge already during the first months after discharge, and
he difference between the patient groups remains through-
ut the follow-up time. In contrast, the SCD curves among
he patients with and without elevated BNP levels start to
iverge relatively late (20 months) after AMI, the diver-
ence becoming larger during longer follow-up (Fig. 2).
ensitivity, specificity, and negative and positive predictive
ccuracy of BNP, LVEF, and their combination as predic-
stratified by the results of natriuretic peptide and ejection fraction (EF)
as at the 60th percentile; (B) for N-terminal atrial natriuretic propeptide
retic peptide (BNP), the best cut-off point was at the 60th quartile; (D)roups
int w
natriuors of SCD are shown in Table 4.
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March 3, 2004:757–63 Natriuretic Peptides as Predictors After AMIISCUSSION
he main findings of this study are that plasma levels of
atriuretic peptides still retain their prognostic power
mong patients who are receiving beta-blocking medication.
urthermore, BNP also predicts the occurrence of SCD,
ndependent of clinical variables and LVEF.
atriuretic peptides as predictors of mortality. Natri-
retic peptides have been shown to be strong predictors of
ardiac and all-cause mortality after AMI (1–9,29,30). In
ost of the previous reports comparing the predictive
ccuracy between the different natriuretic peptides, BNP
as been shown to be superior to N-ANP and ANP as a
rognostic marker (2,8). Also, BNP has been shown to be
ore stable than ANP, with a longer half-life (31), and its
eliability in indicating LV dysfunction after AMI is not as
ependent on the time point of measurement as that of
NP or N-ANP (4).
In the present study, ANP and BNP performed some-
hat better than N-ANP in predicting cardiac mortality. Of
he three, BNP seemed to be the most specific in predicting
CD, but it was clearly inferior to ANP and N-ANP in
redicting non-SCD. The time point of making the peptide
easurement certainly has some effect on the predictive
ccuracy of vasoactive peptides because the secretion of
atriuretic peptides varies with changes in hemodynamics in
he immediate post-AMI period (4). Despite the relatively
igure 2. Kaplan-Meier survival curves among patients with and without
levated brain natriuretic peptide (BNP).
able 4. Sensitivity, Specificity, and Positive, Negative, and Over
entricular Systolic Function for Prediction of Sudden Cardiac D
Parameter
Specificity
(%)
NP 23.0 pmol/l (60th percentile) 61.3
NP 33.9 pmol/l (highest quartile) 75.8
F 40% (lowest quartile) 76.8
F 30% (5th percentile) 95.0
ombination of BNP 23.0 pmol/l and EF 40% 85.2
ombination of BNP 23.0 pmol/l and EF 30% 96.4bbreviations as in Tables 1 and 2.ong time period between AMI and the taking of blood
amples, the present results confirm the previous observa-
ion that vasoactive peptides provide prognostic information
mong post-AMI patients even when medical therapy is
ptimized according to current guidelines.
rediction of SCD after AMI. Several risk markers, such
s autonomic markers, the signal-averaged electrocardio-
ram (ECG), and T-wave alternans, have been extensively
tudied as predictors of SCD after AMI (14–16,21,22,32).
ost of the studies have suggested that these variables
rovide information on the risk of subsequent SCD and
rrhythmia events (14–16,32). However, the majority of
hese observational studies have been performed in the era
ithout optimized medical therapy. For example, in the
utonomic Tone and Reflexes After Myocardial Infarction
ATRAMI) study, showing that autonomic markers predict
ubsequent sudden death, only 20% of patients were
eceiving beta-blocking therapy (14). Similarly, only 13% of
atients were receiving beta-blocking medication in studies
howing that T-wave alternans after AMI predicts SCD
16,32). Our previous analyses of the same population as in
he current study suggested that the arrhythmia risk vari-
bles, such as autonomic markers, signal-averaged ECG,
nd T-wave alternans, lose some of their predictive power
mong post-AMI patients with optimized beta-blocking
herapy (21,22). In the light of these findings, the present
bservations suggest that elevated BNP may have some
otential value in the prediction of SCD among the current
ost-AMI populations.
levated BNP and risk of SCD. A recent study including
atients with chronic HF also showed that elevated BNP
redicts the occurrence of SCD (20). There are some
mportant differences between the previous and the present
tudy. Patients with symptoms of HF and LVEF 35%
ere included in the previous study, and only 30% of the
atients were using beta-blocking medication. The present
tudy confirms that BNP also predicts SCD—independent
f clinical HF and reduced EF—among the post-AMI
atients.
There may be several reasons why BNP provides more
pecific information on the risk of SCD than the other
eptides, or even measurement of LV systolic function.
oth ANP and N-ANP are more closely related to atrial
redictive Accuracies of Brain Natriuretic Peptide and Left
at Different Cut Points
ensitivity
(%)
Positive
Predictive
Accuracy (%)
Negative
Predictive
Accuracy (%)
Overall
Accuracy (%)
73.3 5.4 98.7 61.6
53.3 6.2 98.2 75.2
50.0 6.4 98.0 76.0
18.8 10.7 97.4 92.7
40.0 7.5 97.9 83.9
20.0 14.3 97.6 94.1all P
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Natriuretic Peptides as Predictors After AMI March 3, 2004:757–63olume loading, whereas BNP secretion from the ventricles
s increased during progressing HF (33,34) and is released
rom the ventricles in response to increased pressure,
tretch, and hypertrophy (35). Ventricular stretch, hypertro-
hy, and fibrosis can have significant influences on cardiac
lectrophysiologic properties via mechano-electrical feed-
ack (36–39). Thereby, BNP may be an indirect marker of
he mechanical factors predisposing to the onset and per-
etuation of life-threatening arrhythmias. This is also sup-
orted by an observation that BNP specifically predicted the
ccurrence of SCD late after the index event. It is possible
hat elevated BNP is a marker of LV remodeling occurring
ate after AMI, which then predisposes to sudden arrhyth-
ic death.
linical implications. A significant proportion of post-
MI patients, even with adequate treatment, are still at
igh risk of dying during the first few years after AMI. The
rediction and prevention of SCD is of particular impor-
ance because recent large-scale randomized trials have
ocumented the mortality benefit from prophylactic ICD
herapy in certain high-risk subgroups of patients (19).
ecently, Berger et al. (20) proposed the use of BNP
easurements for determining which patients might benefit
rom ICD placement in chronic HF. The positive predictive
ccuracy of elevated BNP alone in our post-AMI popula-
ion remained relatively low, preventing the recommenda-
ions for widespread screening of the candidacy for ICD
herapy based only on the measurement of BNP. Further-
ore, the accuracy of a low BNP plasma concentration as a
redictor of survival with low risk of SCD was excellent,
uggesting that this simple measurement could be used for
creening purposes to exclude the risk of future SCD and
he need for further risk stratification. The present data
uggest that BNP should also be included as one of the risk
ariables in future studies comparing the various indexes as
redictors of SCD.
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